Lumeda Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Lumeda Inc. - overview
Established
2019
Location
-, CT, US
Primary Industry
Biotechnology
About
Based in Connecticut, US, and founded in 2019, Lumeda Inc. operates as a medical technology company that develops photodynamic therapy (PDT) as a treatment for patients with non-small cell lung cancer (NSCLC) and other thoracic malignancies. The company was co-founded by Paul Sanders and Trevor MacDougall, and is backed by investors including Connecticut Innovations and Cycle Venture Partners from the Series A funding round in April 2021. Lumeda uses Photodynamic Therapy (PDT), a two-stage cancer treatment that involves a photosensitizer drug that collects within cancer cells and then produces cell death upon light activation.
The company's DigiLum™ system is designed to be an effective therapy with minimal side effects to address disease recurrence in NSCLC tumor resection. Lumeda plans to further develop its PDT system, which uses artificial intelligence (AI) and proprietary software and hardware to allow controlled light dosimetry, and expects its first-in-human clinical studies to commence in the middle of 2021.
Current Investors
Connecticut Innovations, Cycle Venture Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.lumedainc.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Lumeda Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.